DOCSLIB.ORG

Age- and Gender-Specific Modulation of Serum Osteopontin and Interferon-Α by Osteopontin Genotype in Systemic Lupus Er

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Age- and Gender-Specific Modulation of Serum Osteopontin and Interferon-Α by Osteopontin Genotype in Systemic Lupus Er Genes and Immunity (2009) 10, 487–494 & 2009 Macmillan Publishers Limited All rights reserved 1466-4879/09 $32.00 www.nature.com/gene ORIGINAL ARTICLE Age- and gender-specific modulation of serum osteopontin and interferon-a by osteopontin genotype in systemic lupus erythematosus SN Kariuki1, JG Moore1, KA Kirou2,MKCrow2, TO Utset1 and TB Niewold1 1Section of Rheumatology, University of Chicago, Chicago, IL, USA and 2Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, USA Osteopontin (OPN) is a multifunctional cytokine involved in long bone remodeling and immune system signaling. Additionally, OPN is critical for interferon-a (IFN-a) production in murine plasmacytoid dendritic cells. We have previously shown that IFN-a is a heritable risk factor for systemic lupus erythematosus (SLE). Genetic variants of OPN have been associated with SLE susceptibility, and one study suggests that this association is particular to men. In this study, the 3 0 UTR SLE-risk variant of OPN (rs9138C) was associated with higher serum OPN and IFN-a in men (P ¼ 0.0062 and P ¼ 0.0087, respectively). In women, the association between rs9138 C and higher serum OPN and IFN-a was restricted to younger subjects, and risk allele carriers showed a strong age-related genetic effect of rs9138 genotype on both serum OPN and IFN-a (Po0.0001). In African- American subjects, the 5 0 region single nucleotide polymorphisms, rs11730582 and rs28357094, were associated with anti- RNP antibodies (odds ratio (OR) ¼ 2.9, P ¼ 0.0038 and OR ¼ 3.9, P ¼ 0.021, respectively). Thus, we demonstrate two distinct genetic influences of OPN on serum protein traits in SLE patients, which correspond to previously reported SLE-risk variants. This study provides a biologic relevance for OPN variants at the protein level, and suggests an influence of this gene on the IFN-a pathway in SLE. Genes and Immunity (2009) 10, 487–494; doi:10.1038/gene.2009.15; published online 2 April 2009 Keywords: systemic lupus erythematosus; interferon-a; osteopontin; age; gender; autoantibodies Introduction IFN-a is clustered in SLE families in both healthy and SLE-affected members, suggesting that high serum IFN-a Systemic lupus erythematosus (SLE) is a prototype is a heritable risk factor for SLE.7 In follow-up studies, systemic autoimmune disorder, typically involving the we have demonstrated two SLE-associated genetic skin, musculoskeletal, renal and hematologic organ polymorphisms, IRF5 and PTPN22, predispose to high systems. Susceptibility to SLE likely arises from a serum IFN-a in SLE patients,8,9 however, much of the complex network of gene–gene and gene–environment genetic variation resulting in heritability of serum IFN-a interactions.1 Although many genetic loci have been remains to be discovered. linked to disease susceptibility, much work remains to Osteopontin/secreted phosphoprotein 1 (OPN) is a integrate these loci into the pathophysiology of the phosphorylated extracellular matrix protein with disease. Recent studies suggest a role for interferon-a a variety of functions, including wound healing, bone (IFN-a) in SLE pathogenesis. IFN-a is a pleiotropic type I formation and remodeling,10 as well as immunological IFN with the potential to break self tolerance by functions such as T-cell activation, Th1 differentiation, activating antigen-presenting cells after uptake of self B-cell activation,11 and macrophage activation and material.2 Serum IFN-a levels are elevated in many SLE chemotaxis.12 Studies have demonstrated high levels of patients, and elevations may correlate with disease OPN in biopsies of inflamed tissues in SLE and other activity.3,4 In addition, a number of patients treated with autoimmune diseases,13,14 and variants of the OPN gene recombinant human IFN-a for malignancy and chronic have been associated with SLE susceptibility.15–17 In a viral hepatitis have developed de novo SLE, which study of 394 Italian SLE patients, two single nucleotide typically resolves after the IFN-a is discontinued.5,6 We polymorphisms (SNPs) in OPN were associated with have previously shown that abnormally high serum SLE, including rs11439060 in the 50 flanking region (odds ratio (OR) ¼ 2.35, P ¼ 0.006) and rs9138 in the 30 UTR (OR ¼ 1.57, P ¼ 0.00094).16 Linkage disequilibrium Correspondence: Dr TB Niewold, Section of Rheumatology, between these two SNPs was low (r2 ¼ 0.23), and logistic University of Chicago, 5841 S Maryland Ave., MC 0930, Chicago, regression models supported an independent genetic IL 60637, USA. E-mail: [email protected] association between each of these SNPs and SLE. Received 8 December 2008; revised and accepted 03 March 2009; A follow-up study including 707 European-American published online 2 April 2009 and 434 African-American SLE patients did not find Osteopontin genotype modulates serum cytokines SN Kariuki et al 488 significant associations between 50 SNPs and SLE, older SLE patients.19 Given the role of OPN in long bone although the rs11439060 variant was not genotyped remodeling and the potential for age-related influences directly.17 This study replicated the association between on OPN expression, we also looked for age-related rs9138 and SLE, although surprisingly the association trends in serum IFN-a and serum OPN levels related to was particular to the male patients in their cohort (13% of OPN genotype. Cytokines were studied as quantitative the SLE patients studied). The previous Italian study did traits in analyses stratified by OPN SNPs, gender and not separate patients by gender for analysis, however, the previously described high IFN-a age groups.19 SLE- male/female ratio in that study was similar (14% male). associated autoantibodies were studied in the patients as The potential influence of OPN genetic variants on categorical traits, analyzed as outcome variables in serum OPN levels is not well described to date. One logistic regression models using OPN SNPs as predictor previous study found that the SLE-associated rs9138 C variables. allele in the 30 UTR was associated with increased serum OPN levels in healthy controls, however, the same association was not seen in the SLE patients.16 In murine models, OPN is essential for IFN-a production down- Results stream of the endosomal Toll-like receptor 9 in plasma- rs9138 C allele was associated with increased IFN-a in male cytoid dendritic cells, likely via interaction with the SLE patients MyD88 adaptor protein.18 Plasmacytoid dendritic cells We analyzed serum IFN-a data in the 40 male SLE are thought to be the major IFN-a producing cells in the patients stratified by OPN genotype at each of the 9 body, and this striking impact of OPN on the murine genotyped SNPs. Diagrams showing the haplotype Toll-like receptor/IFN-a system suggests a potential structure between the nine SNPs in each ancestral relevance for OPN in IFN-a production in human background are shown in Figure 1, and allele frequencies disease. are shown in Supplementary Table 1. The rs9138 C allele In this study, we investigate the association of nine was associated with increased serum IFN-a activity in OPN SNPs with serum IFN-a activity and serum OPN male patients in a dose–response fashion (P ¼ 0.0087; levels in SLE patients, to determine whether genetic Figure 2a). rs9138 is the most consistently replicated SLE- variation at the OPN locus is associated with altered risk SNP in previous case–control genetic studies,15–17 serum levels of IFN-a, OPN or autoantibodies in SLE and this is the SNP which demonstrated a preferential patients in vivo. SNPs previously associated with SLE15–17 association with SLE in men in one previous study.17 and tag SNPs collectively representing 495% of the Other OPN SNPs did not show significant associations known variation in the gene region were included in the with serum IFN-a activity in male patients (P40.4 for study. other SNPs, data not shown). Male patients of all Given that a gender-specific genetic association ancestral backgrounds were analyzed in aggregate, as between the rs9138 SNP in OPN and SLE was detected the number of male subjects was too small to support in one study,17 we separated male and female patients for separate analyses in each ancestral background. Pub- these analyses. Additionally, we have previously shown lished work supports the idea that rs9138 C is a risk that younger SLE patients have higher serum IFN-a than factor for SLE in male subjects of both European and African-American European-American 123456789 123456789 511016 0423 0 48 34 60 58 16 16 75 7 0 11 2 20 21 14 6 47 51 43 10 25 20 20 27 44 6 4 40 24 77 75 10 12 21 78 9 0 0 9 1 53 21 11 10 19 7 31 1 7 9 27 13 11 2 19 9 9 8 13 2 0 5 11 5 9 Hispanic-American 1. rs10516800 2. rs11730582 1234567 89 3. rs28357094 16 9 46 13 3 6 50 0 4. rs2853749 13 19 12 2 22 12 9 5. rs11728697 23 76 0 3 37 51 7 4 3 3 11 6. rs6532040 0 23 7 0 7. rs1126772 2 13 9 8. rs9138 1 4 0 9. rs7655182 Figure 1 Haplotype structures observed in osteopontin (OPN) gene in each ancestral background studied. Darker gray shading in the box plot indicates higher r2 values, and a gene diagram showing the location of each studied single nucleotide polymorphism (SNP) is shown above the box plot. Pairwise r2 values in each square are shown as r2 Â 100, calculated using Haploview 4.0 software. Genes and Immunity Osteopontin genotype modulates serum cytokines SN Kariuki et al 489 Figure 3 Serum interferon-a (IFN-a) activity in female patients stratified by age and osteopontin (OPN) rs9138 genotype.
Load more

Recommended publications
  • Induction of a TRAIL Mediated Suicide Program by Interferon Alpha in Primary E€Usion Lymphoma
    Oncogene (2001) 20, 7029 ± 7040 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Induction of a TRAIL mediated suicide program by interferon alpha in primary eusion lymphoma Ngoc L Toomey1,4, Vadim V Deyev2,4, Charles Wood3, Lawrence H Boise2, Duncan Scott1, Lei Hua Liu1, Lisa Cabral1, Eckhard R Podack2, Glen N Barber2 and William J Harrington Jr*,1 1Department of Medicine University of Miami School of Medicine, Miami, Florida, FL 33136, USA; 2Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, Florida, FL 33136, USA; 3School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, NE 68588, USA Gammaherpes viruses are often detected in lymphomas Virus (EBV) or Human Herpes Virus Type 8 (HHV-8) arising in immunocompromised patients. We have found have been isolated from lymphomas found in im- that Azidothymidine (AZT) alone induces apoptosis in munosuppressed organ transplant recipients, children Epstein Barr Virus (EBV) positive Burkitt's lymphoma with hereditary immunode®ciencies and patients with (BL) cells but requires interferon alpha (IFN-a) to induce acquired immunode®ciency (AIDS) (Swinnen, 1999; apoptosis in Human Herpes Virus Type 8 (HHV-8) Goldsby and Carroll, 1998; Knowles, 1999). Many of positive Primary Eusion Lymphomas (PEL). Our these tumors can be categorized into distinct subtypes analysis of a series of AIDS lymphomas revealed that based on a variety of morphologic and molecular IFN-a selectively induced very high levels of the Death criteria. For example, AIDS associated large cell Receptor (DR) tumor necrosis factor-related apoptosis- diuse or immunoblastic lymphomas (DLCL, IBL) inducing ligand (TRAIL) in HHV-8 positive PEL lines are often EBV positive while AIDS associated Burkitt's and primary tumor cells whereas little or no induction lymphomas (BL) less frequently contain EBV (Gaidano was observed in primary EBV+ AIDS lymphomas and et al., 1994).
    [Show full text]
  • Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection Against Classical Swine Fever Virus
    Article Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus Yusmel Sordo-Puga 1, Marisela Suárez-Pedroso 1 , Paula Naranjo-Valdéz 2, Danny Pérez-Pérez 1, Elaine Santana-Rodríguez 1, Talia Sardinas-Gonzalez 1, Mary Karla Mendez-Orta 1, Carlos A. Duarte-Cano 1, Mario Pablo Estrada-Garcia 1 and María Pilar Rodríguez-Moltó 1,* 1 Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, Havana 10600, Cuba; [email protected] (Y.S.-P.); [email protected] (M.S.-P.); [email protected] (D.P.-P.); [email protected] (E.S.-R.); [email protected] (T.S.-G.); [email protected] (M.K.M.O.); [email protected] (C.A.D.); [email protected] (M.P.E.) 2 Central Laboratory Unit for Animal Health (ULCSA), Havana 11400, Cuba; [email protected] * Correspondence: [email protected]; Tel.: +53-7-2504419 Abstract: Live attenuated C-strain classical swine fever vaccines provide early onset protection. These vaccines confer effective protection against the disease at 5–7 days post-vaccination. It was previously reported that intramuscular administration of the Porvac® vaccine protects against highly virulent Citation: Sordo-Puga, Y.; classical swine fever virus (CSFV) “Margarita” strain as early as seven days post-vaccination. In Suárez-Pedroso, M.; Naranjo-Valdéz, order to identify how rapidly protection against CSFV is conferred after a single dose of the Porvac® P.; Pérez-Pérez, D.; subunit vaccine E2-CD154, 15 swine, vaccinated with a single dose of Porvac®, were challenged Santana-Rodríguez, E.; 3 intranasally at five, three, and one day post-vaccination with 2 × 10 LD50 of the highly pathogenic Sardinas-Gonzalez, T.; Mendez-Orta, Cuban “Margarita” strain of the classical swine fever virus.
    [Show full text]
  • Interferon-Γ Enhances Interleukin 12 Production in Rheumatoid Synovial
    Interferon-γ Enhances Interleukin 12 Production in Rheumatoid Synovial Cells via CD40-CD154 Dependent and Independent Pathways MINETAKE KITAGAWA, HIROSHI SUZUKI, YOSHIHIRO ADACHI, HIROSHI NAKAMURA, SHINICHI YOSHINO, and TAKAYUKI SUMIDA ABSTRACT. Objective. To determine the role of interferon-γ (IFN-γ) in CD40-CD154 dependent production of interleukin 12 (IL-12) by synovial cells of patients with rheumatoid arthritis (RA). Methods. We examined the effects of IFN-γ, tumor necrosis factor-α (TNF-α), and granulocyte- macrophage colony stimulating factor (GM-CSF) on CD40 expression on CD68+ synovial macrophage-lineage cells (SMC). The effects of IFN-γ and soluble CD154 (sCD154) on IL-12 production by RA synovial cells were determined by ELISA. Results. CD68+ SMC expressed substantial levels of CD40. IFN-γ, but not TNF-α or GM-CSF, markedly upregulated CD40 expression on CD68+ SMC. IFN-γ also dose dependently increased IL- γ 12 production by synovial cells. The effects of IFN- on CD40 expression (EC50 = 127.4 U/ml) were observed at a concentration 19 times lower than the effects on IL-12 production (EC50 = 6.8 U/ml). Treatment with IFN-γ at a concentration low enough to augment CD40 expression but not IL-12 production enhanced spontaneous IL-12 production synergy with sCD154. The synergistic enhance- ment of spontaneous IL-12 production was abrogated by CD40-Fc. In contrast, IL-12 production induced by high concentration of IFN-γ was not neutralized by CD40-Fc. Conclusion. IFN-γ enhanced IL-12 production via both CD40-CD154 dependent and independent pathways in RA synovium. IFN-γ may play a crucial role in the development of RA synovitis through regulation of IL-12 production.
    [Show full text]
  • Dysregulated Interferon Response Underlying Severe COVID-19
    viruses Review Dysregulated Interferon Response Underlying Severe COVID-19 LeAnn Lopez y, Peter C. Sang y, Yun Tian y and Yongming Sang * Department of Agricultural and Environmental Sciences, College of Agriculture, Tennessee State University, 3500 John A. Merritt Boulevard, Nashville, TN 37209, USA; [email protected] (L.L.); [email protected] (P.C.S.); [email protected] (Y.T.) * Correspondence: [email protected]; Tel.: +1-615-963-5183 These authors contributed equally. y Academic Editor: Andrew Davidson Received: 27 October 2020; Accepted: 9 December 2020; Published: 13 December 2020 Abstract: Innate immune interferons (IFNs), including type I and III IFNs, constitute critical antiviral mechanisms. Recent studies reveal that IFN dysregulation is key to determine COVID-19 pathogenesis. Effective IFN stimulation or prophylactic administration of IFNs at the early stage prior to severe COVID-19 may elicit an autonomous antiviral state, restrict the virus infection, and prevent COVID-19 progression. Inborn genetic flaws and autoreactive antibodies that block IFN response have been significantly associated with about 14% of patients with life-threatening COVID-19 pneumonia. In most severe COVID-19 patients without genetic errors in IFN-relevant gene loci, IFN dysregulation is progressively worsened and associated with the situation of pro-inflammation and immunopathy, which is prone to autoimmunity. In addition, the high correlation of severe COVID-19 with seniority, males, and individuals with pre-existing comorbidities will be plausibly explained by the coincidence of IFN aberrance in these situations. Collectively, current studies call for a better understanding of the IFN response regarding the spatiotemporal determination and subtype-specificity against SARS-CoV-2 infections, which are warranted to devise IFN-related prophylactics and therapies.
    [Show full text]
  • Pegasys, INN-Peginterferon Alfa-2A
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before 1 April 2005. For scientific information on procedures after this date please refer to module 8B. 1. Introduction Peginterferon alfa-2a is a polyethylene glycol (PEG)-modified form of human recombinant interferon alfa-2a intended for the treatment of adult patients with chronic hepatitis C (CHC) or chronic hepatitis B (CHB). Chronic hepatitis C is a major public health problem: hepatitis C virus (HCV) is responsible for a large proportion of chronic liver disease, accounting for 70% of cases of chronic hepatitis in industrialised countries. Globally there are an estimated 150 million chronic carriers of the virus, including 5 million in Western Europe. Without treatment approximately 30% of those infected with HCV will develop cirrhosis over a time frame of 30 years or more. For those with HCV-related cirrhosis, the prognosis is poor – a significant proportion will develop a life-threatening complication (either decompensated liver disease or an hepatocellular carcinoma) within a few years. The only therapy for those with advanced cirrhosis is liver transplantation, which carries a high mortality. In those who survive transplantation, viral recurrence in the new liver is almost inevitable and a significant proportion of infected liver grafts develop a progressive fibrosis that leads to recurrence of cirrhosis within 5 years. Interferon alfa monotherapy has been shown to be effective for the treatment of chronic hepatitis although sustained response rates occurred in approximately 15 to 30 % of patients treated for long duration (12-18 months). The current reference therapy is interferon alpha in combination with ribavirin, which resulted in an increase in biochemical and virological sustained response rates to approximately 40 % in naïve patients.
    [Show full text]
  • Intracellular Cleavage of Osteopontin by Caspase-8 Modulates Hypoxia/Reoxygenation Cell Death Through P53
    Intracellular cleavage of osteopontin by caspase-8 modulates hypoxia/reoxygenation cell death through p53 Hyo-Jin Kima, Ho-June Leea, Joon-Il Junb, Yumin Oha, Seon-Guk Choia, Hyunjoo Kima, Chul-Woong Chungc, In-Ki Kimd, Il-Sun Parke, Han-Jung Chaef, Hyung-Ryong Kimg, and Yong-Keun Junga,1 aCreative Research Initiative Acceleration Research, School of Biological Science/Bio-Max Institute, Seoul National University, Seoul 151–747, Korea; bDepartment of Life Science, Gwangju Institute of Science and Technology, Gwangju 500–712, Korea; cLG Life Science Research Park, Daejon 305–389, Korea; dOntario Cancer Institute, Toronto, Ontario M5G 2M9, Canada; eDepartment of Bio-Materials Engineering and Molecular Medicine, School of Medicine, Chosun University, Gwangju 501–759, Korea; fSchool of Medicine, Chonbuk National University, Chonbuk 560–180, Korea, and gDepartment of Dental Pharmacology, School of Dentistry, Wonkwang University, Chonbuk 570–749, Korea Edited by Harvey Cantor, Dana-Farber Cancer Institute, Boston, MA, and approved July 20, 2009 (received for review April 3, 2009) Osteopontin (OPN) is highly expressed in cancer patients and plays after massive generation of reactive oxygen species (ROS) and important roles in many stages of tumor progression, such as anti- caspases activation. Several caspases including caspases-8, -9, and -3 apoptosis, proliferation, and metastasis. From functional screening of were reported to be activated during reoxygenation, which is human cDNA library, we isolated OPN as a caspase-8 substrate that required for Hyp/RO-induced cell death (11, 12). Among these regulates cell death during hypoxia/reoxygenation (Hyp/RO). In vitro caspases, caspase-8 is a well known receptor-proximal caspase.
    [Show full text]
  • Induces Antigen Presentation in B Cells Cell-Activating Factor of The
    B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells This information is current as of September 27, 2021. Min Yang, Hidenori Hase, Diana Legarda-Addison, Leena Varughese, Brian Seed and Adrian T. Ting J Immunol 2005; 175:2814-2824; ; doi: 10.4049/jimmunol.175.5.2814 http://www.jimmunol.org/content/175/5/2814 Downloaded from References This article cites 54 articles, 36 of which you can access for free at: http://www.jimmunol.org/content/175/5/2814.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology B Cell Maturation Antigen, the Receptor for a Proliferation-Inducing Ligand and B Cell-Activating Factor of the TNF Family, Induces Antigen Presentation in B Cells1 Min Yang,* Hidenori Hase,* Diana Legarda-Addison,* Leena Varughese,* Brian Seed,† and Adrian T.
    [Show full text]
  • 1208.Full-Text.Pdf
    Published OnlineFirst June 19, 2019; DOI: 10.1158/2159-8290.CD-18-1454 RESEARCH ARTICLE Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Effi cacy in Triple-Negative Breast Cancer Jaclyn Sceneay 1 , 2 , Gregory J. Goreczny 1 , 2 , Kristin Wilson 1 , Sara Morrow 1 , Molly J. DeCristo 1 , 2 , Jessalyn M. Ubellacker1 , 2 , Yuanbo Qin 1 , 2 , Tyler Laszewski 1 , Daniel G. Stover 3 , Victor Barrera 4 , John N. Hutchinson 4 , Rachel A. Freedman 5 , 6 , Elizabeth A. Mittendorf 6 , 7 , and Sandra S. McAllister 1 , 2 , 8 , 9 ABSTRACT Immune checkpoint blockade (ICB) therapy, which targets T cell–inhibitory recep- tors, has revolutionized cancer treatment. Among the breast cancer subtypes, evaluation of ICB has been of greatest interest in triple-negative breast cancer (TNBC) due to its immunogenicity, as evidenced by the presence of tumor-infi ltrating lymphocytes and elevated PD-L1 expression relative to other subtypes. TNBC incidence is equally distributed across the age spectrum, affecting 10% to 15% of women in all age groups. Here we report that increased immune dysfunction with age limits ICB effi cacy in aged TNBC-bearing mice. The tumor microenvironment in both aged mice and patients with TNBC shows decreased IFN signaling and antigen presentation, suggesting failed innate immune activation with age. Triggering innate immune priming with a STING agonist restored response to ICB in aged mice. Our data implicate age-related immune dysfunction as a mechanism of ICB resistance in mice and suggest potential prognostic utility of assessing IFN-related genes in patients with TNBC receiving ICB therapy.
    [Show full text]
  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
    Review Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation Leonor S. Castro 1,†, Guilherme S. Lobo 1,†, Patrícia Pereira 2 , Mara G. Freire 1 ,Márcia C. Neves 1,* and Augusto Q. Pedro 1,* 1 CICECO–Aveiro Institute of Materials, Chemistry Department, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; [email protected] (L.S.C.); [email protected] (G.S.L.); [email protected] (M.G.F.) 2 Centre for Mechanical Engineering, Materials and Processes, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal; [email protected] * Correspondence: [email protected] (M.C.N.); [email protected] (A.Q.P.) † These authors contributed equally to this work. Abstract: The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical Citation: Castro, L.S.; Lobo, G.S.; pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, Pereira, P.; Freire, M.G.; Neves, M.C.; and multiple sclerosis.
    [Show full text]
  • Viewed by the Institutional Lab- M2mws Were Counted, and 1.03106 Viable Cells Were Suspended in Oratory Animal Care and Use Committee of Nagoya City University
    BASIC RESEARCH www.jasn.org Colony-Stimulating Factor-1 Signaling Suppresses Renal Crystal Formation † Kazumi Taguchi,* Atsushi Okada,* Hiroshi Kitamura, Takahiro Yasui,* Taku Naiki,* Shuzo Hamamoto,* Ryosuke Ando,* Kentaro Mizuno,* Noriyasu Kawai,* Keiichi Tozawa,* ‡ ‡ † Kenichi Asano, Masato Tanaka, Ichiro Miyoshi, and Kenjiro Kohri* Departments of *Nephro-urology, and †Comparative and Experimental Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; and ‡Laboratory of Immune Regulation, School of Science, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan ABSTRACT We recently reported evidence suggesting that migrating macrophages (Mws) eliminate renal crystals in hyperoxaluric mice. Mwscanbeinflammatory (M1) or anti-inflammatory (M2), and colony-stimulating factor-1 (CSF-1) mediates polarization to the M2Mw phenotype. M2Mws promote renal tissue repair and regeneration, but it is not clear whether these cells are involved in suppressing renal crystal formation. We investigated the role of M2Mws in renal crystal formation during hyperoxaluria using CSF-1–deficient mice, which lack M2Mws. Compared with wild-type mice, CSF-1–deficient mice had significantly higher amounts of renal calcium oxalate crystal deposition. Treatment with recombinant human CSF-1 increased the expression of M2-related genes and markedly decreased the number of renal crystals in both CSF-1– deficient and wild-type mice. Flow cytometry of sorted renal Mws showed that CSF-1 deficiency resulted in a smaller population of CD11b+F4/80+CD163+CD206hi cells, which represent M2-like Mws. Additionally, transfusion of M2Mws into CSF-1–deficient mice suppressed renal crystal deposition. In vitro phagocytosis assays with calcium oxalate monohydrate crystals showed a higher rate of crystal phagocytosis by M2- polarized Mws than M1-polarized Mws or renal tubular cells.
    [Show full text]
  • Changing RANKL/OPG Mrna Expression in Differentiating Murine Primary Osteoblasts
    451 Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts G P Thomas,SUKBaker, J A Eisman and E M Gardiner Bone and Mineral Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia (Requests for offprints should be addressed to G P Thomas, Bone and Mineral Research Program, Garvan Institute of Medical Research, 384 Victoria St, Sydney, New South Wales 2010, Australia; Email: [email protected]) Abstract Osteoblast–osteoclast coordination is critical in the main- RANKL were lessened in more mature cultures, however. tenance of skeletal integrity. The modulation of osteoclas- The RANKL/OPG ratio, an index of osteoclastogenic togenesis by immature cells of the osteoblastic lineage is stimulus, was therefore increased by 1,25-(OH)2D3 treat- mediated through receptor activator of NFB (RANK), ment at all stages of osteoblastic differentiation, but to a its ligand RANKL, and osteoprotegerin (OPG), a natural lesser degree in cultures after the onset of mineralisation. decoy receptor for RANKL. Here, the expression of OPG Thus the 1,25-(OH)2D3-driven increase in osteoclas- and RANKL in primary mouse osteoblastic cultures was togenic potential of immature osteoblasts appears to be investigated to determine whether the osteoclastogenic mediated by increased RANKL mRNA expression, with stimulus depended on the stage of osteoblastic differentia- mature osteoblasts having relatively decreased osteoclas- tion and the presence of the calciotrophic hormone 1,25- togenic activity due to increased OPG mRNA expression. dihydroxyvitamin D3 (1,25-(OH)2D3). These findings suggest a possible mechanism for the OPG mRNA expression was increased in osteoblastic recently proposed negative regulatory role of mature cultures after the onset of mineralisation relative to less osteoblasts on osteoclastogenesis and indicate that the mature cultures, but did not alter in response to 1,25- relative proportions of immature and mature osteoblasts in (OH)2D3 treatment.
    [Show full text]
  • Pegasys®) Peginterferon Alfa-2B (Peg-Intron®
    Peginterferon alfa-2a (Pegasys®) Peginterferon alfa-2b (Peg-Intron®) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: Pegylated Interferons BRAND (generic) NAME: Pegasys (peginterferon alfa-2a) Single-use vial 180 mcg/1.0 mL; Prefilled syringe 180 mcg/0.5 mL Peg-Intron (peginterferon alfa-2b) Single-use vial (with 1.25 mL diluent) and REDIPEN®: 50 mcg, 80 mcg, 120 mcg, 150 mcg per 0.5 mL. FDA-APPROVED INDICATIONS PEG-Intron (peginterferon alfa-2b): Combination therapy with ribavirin: • Chronic Hepatitis C (CHC) in patients 3 years of age and older with compensated liver disease. • Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. Monotherapy: CHC in patients (18 years of age and older) with compensated liver disease previously untreated with interferon alpha. Pegasys (Peginterferon alfa-2a): • Treatment of Chronic Hepatitis C (CHC) in adults with compensated liver disease not previously treated with interferon alpha, in patients with histological evidence of cirrhosis and compensated liver disease, and in adults with CHC/HIV coinfection and CD4 count > 100 cells/mm3. o Combination therapy with ribavirin is recommended unless patient has contraindication to or significant intolerance to ribavirin. Pegasys monotherapy is indicated for: • Treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated
    [Show full text]